Compare Abeona Therapeutics Inc (ABEO) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Logitech International SA — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Logitech International SA trades at $97.21 (market cap $13.85B). The key difference: Logitech International SA is far larger — about 37.1× Abeona Therapeutics Inc's market cap, and Logitech International SA pays a 1.75% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LOGI | |
|---|---|---|
Market Cap | $373.32M | $13.85B |
Sector | Health | Technology |
52-Week High | $7.23 | $126.69 |
52-Week Low | $4.17 | $85.84 |
Enterprise Value | $228.22M | $12.20B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Logitech (LOGI) trades at $97.11, up 3.31% with strong profitability metrics including 43.2% gross margin and 32.78% ROE. The stock shows bearish technical signals despite recent earnings beats, with Q1 2026 EPS of $1.13 exceeding expectations. Recent developments include new gaming partnerships and product launches like the G3 Series and Mobi Fold mouse. Cash flow trends show operational strength with $843M generated in 2025, though net cash flow was slightly negative at -$18M.
Logitech presents a mixed outlook with robust fundamentals offset by technical weakness. The 26% upside to consensus price target of $121.33 offers potential, but bearish moving averages and competitive pressures in peripherals market pose risks. Enterprise momentum and AI-enabled products provide growth catalysts, though investor sentiment remains divided with equal buy/sell analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
